The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD-Reference-Cited by-同舟云学术

The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD

Published:2021-10-02 Issue: Volume: Page:
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

McKinley Emily C.^ORCID,Bittner Vera A.,Brown Todd M.,Chen Ligong,Exter Jason,Farkouh Michael E.,Huang Lei,Jackson Elizabeth A.,Levitan Emily B.,Orroth Kate K.,Reading Stephanie R.,Rosenson Robert S.,Safford Monika M.,Woodward Mark,Muntner Paul,Colantonio Lisandro D.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10557-021-07268-x.pdf

Reference37 articles.

1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129:S1–45. https://www.ahajournals.org/doi/10.1161/01.cir.0000437738.63853.7a.

2. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72. https://doi.org/10.1093/eurheartj/ehx144.

3. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5.

4. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97. http://www.nejm.org/doi/10.1056/NEJMoa1410489.

5. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107. http://www.nejm.org/doi/10.1056/NEJMoa1801174.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cholesterol lowering therapy is highly efficacious in reducing atherosclerotic cardiovascular disease risk but grossly underutilized: How do we move the needle?;American Heart Journal;2024-08

2. Management of dyslipidemia after atherosclerotic cardiovascular event: Still a long way to go…and we know it;International Journal of Cardiology;2024-07

3. Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline;American Heart Journal Plus: Cardiology Research and Practice;2022-09